Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study

被引:20
作者
Sharma, Sudhir [1 ]
Lal, Vivek [1 ]
Prabhakar, Sudesh [1 ]
Agarwal, Ritesh [2 ]
机构
[1] Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh 160012, India
[2] Postgrad Inst Med Educ & Res, Dept Pulm Med & Crit Care, Chandigarh 160012, India
关键词
Intravenous immunoglobulins; mechanical ventilation; myasthenic crisis; myasthenia gravis; plasma exchange; INTRAVENOUS IMMUNOGLOBULIN; PLASMA-EXCHANGE; GRAVIS; COMPLICATIONS; MORTALITY; FEATURES; FAILURE;
D O I
10.4103/0972-2327.112466
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The present understanding of the clinical course, complications, and outcome of myasthenic crisis (MC) is based chiefly on observational studies and retrospective case series. Aim: To study the baseline demographic and clinical variables, risk factors, complications, outcome, and mortality in patients of MC. Materials and Methods: All patients of myasthenia gravis (MG) who presented with myasthenic crisis between July 2009 and December 2010 were included. Results: Ten patients of MC were included in this study. The median age of the patients was 40.5 years (range 14-71 years). Seven were females and three were males. Nine had generalized MG and one patient had oculobulbar involvement only. Median duration of disease was 3 years (range 1 month to17 years). Two patients had thymoma. Two patients had history of thymectomy in the past. Infection was the most common triggering factor accounting for five cases (50%) followed by inadequate treatment/drug withdrawal in three (30%) and steroid initiation and hypokalemia in the remaining two patients (20%). Median duration of MC was 12 days (range 3-28 days). Mortality was in 3 out of 10 (30%) during MC. Management in the intensive care unit (ICU) and treatment with plasma exchange/intravenous immunoglobulins were associated with good outcome. Conclusions: Ventilator support and management in intensive care unit are the most important components in the management of MC. The high mortality rate seen in present study may be more reflective of the actual ground reality in resource constrained developing countries, however, larger prospective studies are needed to confirm these findings.
引用
收藏
页码:203 / 207
页数:5
相关论文
共 24 条
[1]   Inflammatory myopathy in myasthenia gravis [J].
Aarli, JA .
CURRENT OPINION IN NEUROLOGY, 1998, 11 (03) :233-234
[2]  
Aggarwal AN, 2002, NEUROL INDIA, V50, P348
[3]  
Calin C, 2009, Rom J Intern Med, V47, P179
[4]   Myasthenic crisis [J].
Chaudhuri, A. ;
Behan, P. O. .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2009, 102 (02) :97-107
[5]   ASPECTS OF THE NATURAL-HISTORY OF MYASTHENIA-GRAVIS - CRISIS AND DEATH [J].
COHEN, MS ;
YOUNGER, D .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1981, 377 (DEC) :670-677
[6]   VENTILATORY FAILURE IN MYASTHENIA-GRAVIS [J].
FERGUSON, IT ;
MURPHY, RP ;
LASCELLES, RG .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1982, 45 (03) :217-222
[7]  
Fink Matthew E., 1993, P351
[8]   Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis [J].
Gajdos, P ;
Chevret, S ;
Clair, B ;
Tranchant, C ;
Chastang, C .
ANNALS OF NEUROLOGY, 1997, 41 (06) :789-796
[9]   Intravenous immunoglobulin for myasthenia gravis [J].
Gajdos, P. ;
Chevret, S. ;
Toyka, K. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01)
[10]   HEART IN MYASTHENIA-GRAVIS [J].
GIBSON, TC .
AMERICAN HEART JOURNAL, 1975, 90 (03) :389-396